Literature DB >> 8630377

Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia.

J M Cayuela1, A Madani, L Sanhes, M H Stern, F Sigaux.   

Abstract

No constant genetic alteration has yet been unravelled in T-cell acute lymphoblastic leukemia (T-ALL), and, to date, the most frequent alteration, the SIL-TAL1 deletion, is found in approximately 20% of cases. Recently, two genes have been identified, the multiple tumor-suppressor gene 1 (MTS1) and multiple tumor-suppressor gene 2 (MTS2), whose products inhibit cell cycle progression. A characterization of the MTS locus organization allowed to determine the incidence of MTS1 and MTS2 inactivation in T-ALL. MTS1 and MTS2 configurations were determined by Southern blotting using 8 probes in 59 patients with T-ALL (40 children and 19 adults). Biallelic MTS1 inactivation by deletions and/or rearrangements was observed in 45 cases (76%). Monoallelic alterations were found in 6 cases (10%). The second MTS1 allele was studied in the 4 cases with available material. A point mutation was found in 2 cases. The lack of MTS1 mRNA expression was observed by Northern blot analysis in a third case. A normal single-strand conformation polymorphism pattern of MTS1 exons 1alpha and 2 was found and MTS1 RNA was detected in the fourth case, but a rearrangement occurring 5' to MTS1 exon 1 alpha deleting MTS1 exon 1Beta was documented. One case presented a complex rearrangement. Germline configuration for MTS1 and MTS2 was found in only 7 cases. The localization of the 17 breakpoints occurring in the MTS locus were determined. Ten of them (59%) are clustered in a 6-kb region located 5 kb downstream to the newly identified MTS1 exon 1Beta. No rearrangement disrupting MTS2 was detected and more rearrangements spared MTS2 than MTS1 (P<.01). MTS1 but not MTS2 RNA was detected by Northern blotting in the human thymus. These data strongly suggest that MTS1 is the functional target of rearrangements in T-ALL. MTS1 inactivation, observed in at least 80% of T-ALL, is the most consistent genetic defect found in this disease to date.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630377

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Inhibition of T-cell acute lymphoblastic leukemia proliferation in vivo by re-expression of the p16INK4a tumor suppressor gene.

Authors:  K Schoppmeyer; P S Norris; M Haas
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

Review 2.  The CDKN2A (p16) gene and human cancer.

Authors:  W D Foulkes; T Y Flanders; P M Pollock; N K Hayward
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

3.  TLX1/HOX11-mediated disruption of primary thymocyte differentiation prior to the CD4+CD8+ double-positive stage.

Authors:  Bronwyn M Owens; Teresa S Hawley; Lisa M Spain; Kristi A Kerkel; Robert G Hawley
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

4.  Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression.

Authors:  R Villuendas; M Sánchez-Beato; J C Martínez; A I Saez; B Martinez-Delgado; J F García; M S Mateo; L Sanchez-Verde; J Benítez; P Martínez; M A Piris
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

5.  Expression of p16/INK4a in posttransplantation lymphoproliferative disorders.

Authors:  A Martin; F Baran-Marzak; S El Mansouri; C Legendre; V Leblond; F Charlotte; F Davi; D Canioni; M Raphaël
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

6.  Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia.

Authors:  M Chilosi; C Doglioni; Z Yan; M Lestani; F Menestrina; C Sorio; A Benedetti; F Vinante; G Pizzolo; G Inghirami
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

7.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.

Authors:  Salima Hacein-Bey-Abina; Alexandrine Garrigue; Gary P Wang; Jean Soulier; Annick Lim; Estelle Morillon; Emmanuelle Clappier; Laure Caccavelli; Eric Delabesse; Kheira Beldjord; Vahid Asnafi; Elizabeth MacIntyre; Liliane Dal Cortivo; Isabelle Radford; Nicole Brousse; François Sigaux; Despina Moshous; Julia Hauer; Arndt Borkhardt; Bernd H Belohradsky; Uwe Wintergerst; Maria C Velez; Lily Leiva; Ricardo Sorensen; Nicolas Wulffraat; Stéphane Blanche; Frederic D Bushman; Alain Fischer; Marina Cavazzana-Calvo
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

8.  p16INK4A tumor suppressor gene expression and CD3epsilon deficiency but not pre-TCR deficiency inhibit TAL1-linked T-lineage leukemogenesis.

Authors:  Magali Fasseu; Peter D Aplan; Martine Chopin; Nicolas Boissel; Jean-Christophe Bories; Jean Soulier; Harald von Boehmer; François Sigaux; Armelle Regnault
Journal:  Blood       Date:  2007-05-16       Impact factor: 22.113

9.  Effect of p16 on glucocorticoid response in a B-cell lymphoblast cell line.

Authors:  Sun-Young Kim; Kyung-Yil Lee; Dae-Chul Jeong; Hak-Ki Kim
Journal:  Korean J Pediatr       Date:  2010-07-31

10.  NF-κB in T-cell Acute Lymphoblastic Leukemia: Oncogenic Functions in Leukemic and in Microenvironmental Cells.

Authors:  Nuno R Dos Santos; Marinella N Ghezzo; Ricardo C da Silva; Mónica T Fernandes
Journal:  Cancers (Basel)       Date:  2010-11-05       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.